T2 Biosystems (TTOO) Appoints Laura Adams to Its Board

T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately.

“We are excited to have Laura join the T2 Biosystems Board of Directors,” said John Sperzel, Chairman and CEO at T2 Biosystems. “Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory.”

Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing leadership for the NAM Digital Health and Evidence Mobilization portfolios. Her primary expertise is digital health transformation, healthcare innovation, and human-centered care and for the past 20 years has held leadership positions across a wide variety of healthcare focused organizations and as a founding member of multiple healthcare IT companies.

Of note, from 2001 to 2019, Ms. Adams served as the the founding President and CEO of the Rhode Island Quality Institute (RIQI), an organization enabling the best healthcare for the state by providing and connecting trusted data. As part of her tenure she led the Rhode Island Statewide ICU Collaborative as Principal Investigator driving a 62% decrease in catheter-related central line infections; a 48% drop in ventilator-associated pneumonia; a 37% reduction in sepsis mortality; and an estimated $25M in avoided costs. During her time at RIQI, Health Data Management named her one of their 2018 Most Powerful Women in Health IT in the Thought Leader category and Becker’s Hospital Review named her to the 2018 and 2019 lists of Female Health IT Leaders to Know.

Previously, Ms. Adams also chaired the Institute of Medicine’s (IOM) Planning Committee for the “Digital Infrastructure for Population Health and a Learning Healthcare System” initiative. Ms. Adams was Founder, President and CEO of Decision Support Systems, a New York-based company specializing in Internet-based healthcare decision support. Laura Adams has been a long-time faculty member of the Institute for Healthcare Improvement (IHI) in Boston. She serves on the board of Translational Medicine Accelerator (TMA), a Boston-based precision medicine company focusing on patients with recalcitrant and rare diseases; and the Oversight Council for the MA Center for Health Information and Analysis. Ms. Adams earned a Master of Science from the University of Colorado Health Sciences Center, and a B.S. from the University of Northern Colorado, of which she was named Distinguished Alumnus in 2010.

“I am thrilled to join the T2 Biosystems Board of Directors and to assist this team driving innovation focused on a crucial unmet need in healthcare,” said Laura Adams. “Over my career I have addressed the unacceptable risks and costs for patients and the healthcare system caused by reliance on blood culture diagnostics to administer targeted therapy for patients suspected of sepsis. I believe T2’s transformative culture-independent diagnostics can improve the standard of care for patients at risk of sepsis.”

You May Also Be Interested In

• Red Violet (RDVT) Announces Board Changes
• Arvinas Inc. (ARVN) Appoints Randy Teel as Chief Business Officer
• Splash Beverage Group Inc. (SBEV) Appoints Julius Ivancsits as CFO